Frontiers

Upfront - The Director's Perspective

Cancer Care Past, Future, Present Many research-based advances in cancer care have been made since the signing of the National Cancer Act 40 years ago, and they have steadily improved survivorship rates and quality of life ...[Read more]
Published: Feb-14-12 | 1  Comment | 0  Link to this post

Frontline

Ready for Prime Time Genetic predictors of tumor aggressiveness can often help make treatment decisions By RICHARD M. GOLDBERG, MD, physician-in-chief, Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and R ...[Read more]
Published: Feb-14-12 | 0  Comment | 0  Link to this post

Breakthrough

ADVERSE INTERACTION Study Urges Caution With Lenalidomide Dosage By MITCH PHELPS, MD, OSUCCC-James Experimental Therapeutics Program A multiple myeloma study at Ohio State’s Comprehensive Cancer Center – Jame ...[Read more]
Published: Feb-14-12 | 0  Comment | 0  Link to this post

Of Note

AWARDS AND HONORS MARTHA ANN BELURY, PhD, professor of Human Nutrition, of Endocrinology, Diabetes and Metabolism, and of Public Health, has been elected an American Association for the Advancement of Science (AAAS) fellow, for contributio ...[Read more]
Published: Feb-14-12 | 0  Comment | 0  Link to this post

Survivorship 2012

SURVIVORSHIP 2012 Today, more people are surviving longer after cancer treatment, and more of their needs are being addressed by research and included in the continuum of care. By BOB HECKER When Joe Flynn, DO, MPH, co ...[Read more]
Published: Feb-14-12 | 2  Comments | 0  Link to this post

Foreign Occupiers

Metastatic tumors cause the vast majority of cancer deaths. Bone metastases are particularly debilitating. OSUCCC – James researchers are working to understand how they happen and how to block them. By DARRELL E. WARD ...[Read more]
Published: Feb-14-12 | 0  Comment | 0  Link to this post

A Quiet Evolution

A Quiet Evolution P4 medicine promises to promote wellness, lower healthcare costs and improve treatment outcomes. BY DAVE SLAYBAUGH Recent and emerging technologies and several decades of research are transforming the ...[Read more]
Published: Feb-14-12 | 0  Comment | 0  Link to this post

Bench to Bedside

A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Oropharynx HYPOTHESIS: Administration of IL-12 will enhance the antitumor activity of ...[Read more]
Published: Feb-14-12 | 4  Comments | 0  Link to this post

 Next >>